MiNK Therapeutics shared a post on LinkedIn about a recent article by Eleni Chantzoura et al. published in Cancer Immunology Research:
“We’re excited to share new research on MiNK-215, our next-generation ‘off-the-shelf’ cell therapy designed to help the immune system break through the tough barriers that protect many solid tumors.
The findings published in ‘Cancer Immunology Research‘ show that MiNK-215 can clear out the harmful fibroblasts that shield tumors and wake up the immune system, allowing immune cells to get in and do their job.
This approach could offer a new path forward for people with cancers that have been resistant to today’s immunotherapies.
Proud of the MiNK team and our collaborators for advancing this important science.”
Title: The allogeneic FAP-CAR-IL15 iNKT therapy MiNK-215 remodels the tumor stroma to enhance antitumor immunity
Authors: Eleni Chantzoura, Efrat Altman-Sharoni, Xavier Michelet, Martyna C. Popis, Magdalena Niedzielska, Bishnu Joshi, Reed Masakayan, Gerard Rubi-Sans, Stephen Addis, Justin G. Keith, Shanmugarajan Krishnan, Jin San Choi, Stephanie Sanders, Alvaro Sebastian-Yague, Shannon K. Boi, Moira Pinzan-Rossi, Georgios Antonopoulos, Paul Ibbett, Deborah E. Wright, Olivier Le Tonqueze, Nick Kushner, Chinar Pathak, Kah Teong Soh, Amy L. Chalmers, Rachel Smith, Vignesh Venkatraman, Sara Farahi, John Pravin, Priyadarshini Iyer, Emmanuel Briend, Olga Ignatovich, Marco A. Purbhoo, Tyler J. Curiel, Mark A. Exley, Robert B. Stein, Enoch Kim, Jennifer S. Buell, Marc A. van Dijk, Dhan Chand
Read the Full Article on Cancer Immunology Research
More posts about MiNK Therapeutics.